D
USANA Health Sciences, Inc.
USNA
$33.67
$0.712.15%
D
Sell
4/17/2024Downgrade
USANA Health Sciences, Inc. (USNA) was downgraded to D from D+ on 4/17/2024 due to a decline in the volatility index and total return index.
USANA Health Sciences, Inc. (USNA) was downgraded to D from D+ on 4/17/2024 due to a decline in the volatility index and total return index.
D
Sell
2/28/2024Upgraded
USANA Health Sciences, Inc. (USNA) was upgraded to D+ from D on 2/28/2024 due to a noticeable increase in the growth index, solvency index and valuation index. Earnings per share increased from $0.5896 to $0.8702, EBIT increased 37.55% from $17.61M to $24.22M, and operating cash flow increased 17.04% from $22.23M to $26.02M.
USANA Health Sciences, Inc. (USNA) was upgraded to D+ from D on 2/28/2024 due to a noticeable increase in the growth index, solvency index and valuation index. Earnings per share increased from $0.5896 to $0.8702, EBIT increased 37.55% from $17.61M to $24.22M, and operating cash flow increased 17.04% from $22.23M to $26.02M.
D
Sell
2/1/2024Downgrade
USANA Health Sciences, Inc. (USNA) was downgraded to D from D+ on 2/1/2024 due to a decline in the total return index and efficiency index.
USANA Health Sciences, Inc. (USNA) was downgraded to D from D+ on 2/1/2024 due to a decline in the total return index and efficiency index.
D
Sell
1/11/2024Upgraded
USANA Health Sciences, Inc. (USNA) was upgraded to D+ from D on 1/11/2024 due to an increase in the total return index and valuation index.
USANA Health Sciences, Inc. (USNA) was upgraded to D+ from D on 1/11/2024 due to an increase in the total return index and valuation index.
D
Sell
12/27/2023Downgrade
USANA Health Sciences, Inc. (USNA) was downgraded to D from D+ on 12/27/2023 due to a decline in the volatility index, total return index and efficiency index. Net income declined 34.38% from $17.29M to $11.35M.
USANA Health Sciences, Inc. (USNA) was downgraded to D from D+ on 12/27/2023 due to a decline in the volatility index, total return index and efficiency index. Net income declined 34.38% from $17.29M to $11.35M.
D
Sell
8/10/2023Downgrade
USANA Health Sciences, Inc. (USNA) was downgraded to D+ from C- on 8/10/2023 due to a noticeable decline in the growth index, efficiency index and solvency index. Operating cash flow declined 25.57% from $12.83M to $9.55M, EBIT declined 9.11% from $26.85M to $24.4M, and earnings per share declined from $0.95 to $0.89.
USANA Health Sciences, Inc. (USNA) was downgraded to D+ from C- on 8/10/2023 due to a noticeable decline in the growth index, efficiency index and solvency index. Operating cash flow declined 25.57% from $12.83M to $9.55M, EBIT declined 9.11% from $26.85M to $24.4M, and earnings per share declined from $0.95 to $0.89.
C
Hold
4/12/2023Upgraded
USANA Health Sciences, Inc. (USNA) was upgraded to C- from D+ on 4/12/2023 due to an increase in the volatility index, growth index and solvency index. Operating cash flow increased 38.93% from $29.13M to $40.46M, and the quick ratio increased from 1.96 to 2.06.
USANA Health Sciences, Inc. (USNA) was upgraded to C- from D+ on 4/12/2023 due to an increase in the volatility index, growth index and solvency index. Operating cash flow increased 38.93% from $29.13M to $40.46M, and the quick ratio increased from 1.96 to 2.06.
D
Sell
2/14/2023Upgraded
USANA Health Sciences, Inc. (USNA) was upgraded to D+ from D on 2/14/2023 due to an increase in the total return index.
USANA Health Sciences, Inc. (USNA) was upgraded to D+ from D on 2/14/2023 due to an increase in the total return index.
D
Sell
11/21/2022Downgrade
USANA Health Sciences, Inc. (USNA) was downgraded to D from D+ on 11/21/2022 due to a decline in the total return index, growth index and volatility index. EBIT declined 22.94% from $29.37M to $22.63M, earnings per share declined from $0.997 to $0.7767, and total revenue declined 11.79% from $264.47M to $233.3M.
USANA Health Sciences, Inc. (USNA) was downgraded to D from D+ on 11/21/2022 due to a decline in the total return index, growth index and volatility index. EBIT declined 22.94% from $29.37M to $22.63M, earnings per share declined from $0.997 to $0.7767, and total revenue declined 11.79% from $264.47M to $233.3M.
D
Sell
8/10/2022Downgrade
USANA Health Sciences, Inc. (USNA) was downgraded to D+ from C- on 8/10/2022 due to a substantial decline in the growth index, valuation index and total return index. Operating cash flow declined 25.83% from $19.7M to $14.61M, earnings per share declined from $1.15 to $0.997, and EBIT declined 11.19% from $33.07M to $29.37M.
USANA Health Sciences, Inc. (USNA) was downgraded to D+ from C- on 8/10/2022 due to a substantial decline in the growth index, valuation index and total return index. Operating cash flow declined 25.83% from $19.7M to $14.61M, earnings per share declined from $1.15 to $0.997, and EBIT declined 11.19% from $33.07M to $29.37M.
C
Hold
6/23/2022Downgrade
USANA Health Sciences, Inc. (USNA) was downgraded to C- from C on 6/23/2022 due to a decline in the volatility index and total return index.
USANA Health Sciences, Inc. (USNA) was downgraded to C- from C on 6/23/2022 due to a decline in the volatility index and total return index.
C
Hold
6/8/2022Upgraded
USANA Health Sciences, Inc. (USNA) was upgraded to C from C- on 6/8/2022 due to an increase in the volatility index and total return index.
USANA Health Sciences, Inc. (USNA) was upgraded to C from C- on 6/8/2022 due to an increase in the volatility index and total return index.
C
Hold
5/24/2022Downgrade
USANA Health Sciences, Inc. (USNA) was downgraded to C- from C on 5/24/2022 due to a large decline in the total return index and volatility index.
USANA Health Sciences, Inc. (USNA) was downgraded to C- from C on 5/24/2022 due to a large decline in the total return index and volatility index.
C
Hold
3/4/2022Downgrade
USANA Health Sciences, Inc. (USNA) was downgraded to C from C+ on 3/4/2022 due to a large decline in the growth index, valuation index and total return index. Operating cash flow declined 33.52% from $37.49M to $24.92M, earnings per share declined from $1.36 to $1.0327, and EBIT declined 22.73% from $40.77M to $31.51M.
USANA Health Sciences, Inc. (USNA) was downgraded to C from C+ on 3/4/2022 due to a large decline in the growth index, valuation index and total return index. Operating cash flow declined 33.52% from $37.49M to $24.92M, earnings per share declined from $1.36 to $1.0327, and EBIT declined 22.73% from $40.77M to $31.51M.
C
Hold
12/2/2021Upgraded
USANA Health Sciences, Inc. (USNA) was upgraded to C+ from C on 12/2/2021 due to an increase in the volatility index, total return index and valuation index.
USANA Health Sciences, Inc. (USNA) was upgraded to C+ from C on 12/2/2021 due to an increase in the volatility index, total return index and valuation index.
C
Hold
11/16/2021Downgrade
USANA Health Sciences, Inc. (USNA) was downgraded to C from C+ on 11/16/2021 due to a significant decline in the growth index, valuation index and solvency index. Earnings per share declined from $1.87 to $1.36, EBIT declined 24.11% from $53.72M to $40.77M, and total revenue declined 18.55% from $336.84M to $274.35M.
USANA Health Sciences, Inc. (USNA) was downgraded to C from C+ on 11/16/2021 due to a significant decline in the growth index, valuation index and solvency index. Earnings per share declined from $1.87 to $1.36, EBIT declined 24.11% from $53.72M to $40.77M, and total revenue declined 18.55% from $336.84M to $274.35M.
C
Hold
10/15/2021Upgraded
USANA Health Sciences, Inc. (USNA) was upgraded to C+ from C on 10/15/2021 due to an increase in the volatility index.
USANA Health Sciences, Inc. (USNA) was upgraded to C+ from C on 10/15/2021 due to an increase in the volatility index.
C
Hold
9/16/2021Downgrade
USANA Health Sciences, Inc. (USNA) was downgraded to C from C+ on 9/16/2021 due to a decline in the volatility index and solvency index.
USANA Health Sciences, Inc. (USNA) was downgraded to C from C+ on 9/16/2021 due to a decline in the volatility index and solvency index.
C
Hold
3/9/2021Upgraded
USANA Health Sciences, Inc. (USNA) was upgraded to C+ from C on 3/9/2021 due to a major increase in the growth index, solvency index and efficiency index. Net income increased 29.91% from $30.51M to $39.63M, earnings per share increased from $1.44 to $1.8608, and EBIT increased 15.84% from $45.36M to $52.54M.
USANA Health Sciences, Inc. (USNA) was upgraded to C+ from C on 3/9/2021 due to a major increase in the growth index, solvency index and efficiency index. Net income increased 29.91% from $30.51M to $39.63M, earnings per share increased from $1.44 to $1.8608, and EBIT increased 15.84% from $45.36M to $52.54M.
C
Hold
8/21/2020Downgrade
USANA Health Sciences, Inc. (USNA) was downgraded to C from C+ on 8/21/2020 due to a decline in the total return index and valuation index.
USANA Health Sciences, Inc. (USNA) was downgraded to C from C+ on 8/21/2020 due to a decline in the total return index and valuation index.
C
Hold
8/6/2020Upgraded
USANA Health Sciences, Inc. (USNA) was upgraded to C+ from C on 8/6/2020 due to an increase in the total return index and growth index. Earnings per share increased from $1.23 to $1.32, operating cash flow increased 6.02% from $30.79M to $32.64M, and EBIT increased 1.47% from $39.01M to $39.59M.
USANA Health Sciences, Inc. (USNA) was upgraded to C+ from C on 8/6/2020 due to an increase in the total return index and growth index. Earnings per share increased from $1.23 to $1.32, operating cash flow increased 6.02% from $30.79M to $32.64M, and EBIT increased 1.47% from $39.01M to $39.59M.
C
Hold
5/20/2019Downgrade
USANA Health Sciences, Inc. (USNA) was downgraded to C from C+ on 5/20/2019 due to a large decline in the growth index, total return index and volatility index. Operating cash flow declined 86.34% from $40.43M to $5.52M, EBIT declined 27.93% from $48.57M to $35M, and earnings per share declined from $1.3203 to $1.01.
USANA Health Sciences, Inc. (USNA) was downgraded to C from C+ on 5/20/2019 due to a large decline in the growth index, total return index and volatility index. Operating cash flow declined 86.34% from $40.43M to $5.52M, EBIT declined 27.93% from $48.57M to $35M, and earnings per share declined from $1.3203 to $1.01.
C
Hold
4/15/2019Downgrade
USANA Health Sciences, Inc. (USNA) was downgraded to C+ from B- on 4/15/2019 due to a decline in the volatility index.
USANA Health Sciences, Inc. (USNA) was downgraded to C+ from B- on 4/15/2019 due to a decline in the volatility index.
B
Buy
3/29/2019Downgrade
USANA Health Sciences, Inc. (USNA) was downgraded to B- from B on 3/29/2019 due to a decline in the volatility index and total return index.
USANA Health Sciences, Inc. (USNA) was downgraded to B- from B on 3/29/2019 due to a decline in the volatility index and total return index.
B
Buy
3/4/2019Upgraded
USANA Health Sciences, Inc. (USNA) was upgraded to B from B- on 3/4/2019 due to a significant increase in the growth index and valuation index. EBIT increased 6.71% from $45.51M to $48.57M, earnings per share increased from $1.24 to $1.3203, and total revenue increased 0.76% from $296.77M to $299.02M.
USANA Health Sciences, Inc. (USNA) was upgraded to B from B- on 3/4/2019 due to a significant increase in the growth index and valuation index. EBIT increased 6.71% from $45.51M to $48.57M, earnings per share increased from $1.24 to $1.3203, and total revenue increased 0.76% from $296.77M to $299.02M.
B
Buy
2/15/2019Upgraded
USANA Health Sciences, Inc. (USNA) was upgraded to B- from C+ on 2/15/2019 due to an increase in the volatility index and valuation index.
USANA Health Sciences, Inc. (USNA) was upgraded to B- from C+ on 2/15/2019 due to an increase in the volatility index and valuation index.
C
Hold
11/14/2018Downgrade
USANA Health Sciences, Inc. (USNA) was downgraded to C+ from B- on 11/14/2018 due to a significant decline in the total return index, growth index and efficiency index. EBIT declined 11% from $51.14M to $45.51M, earnings per share declined from $1.36 to $1.24, and net income declined 8.46% from $33.91M to $31.04M.
USANA Health Sciences, Inc. (USNA) was downgraded to C+ from B- on 11/14/2018 due to a significant decline in the total return index, growth index and efficiency index. EBIT declined 11% from $51.14M to $45.51M, earnings per share declined from $1.36 to $1.24, and net income declined 8.46% from $33.91M to $31.04M.
B
Buy
10/1/2018Downgrade
USANA Health Sciences, Inc. (USNA) was downgraded to B- from B on 10/1/2018 due to a decline in the total return index.
USANA Health Sciences, Inc. (USNA) was downgraded to B- from B on 10/1/2018 due to a decline in the total return index.
B
Buy
8/22/2018Upgraded
USANA Health Sciences, Inc. (USNA) was upgraded to B from B- on 8/22/2018 due to an increase in the growth index, total return index and volatility index. Operating cash flow increased 93.03% from $19.52M to $37.68M, EBIT increased 18.58% from $43.13M to $51.14M, and earnings per share increased from $1.19 to $1.36.
USANA Health Sciences, Inc. (USNA) was upgraded to B from B- on 8/22/2018 due to an increase in the growth index, total return index and volatility index. Operating cash flow increased 93.03% from $19.52M to $37.68M, EBIT increased 18.58% from $43.13M to $51.14M, and earnings per share increased from $1.19 to $1.36.
B
Buy
5/11/2018Upgraded
USANA Health Sciences, Inc. (USNA) was upgraded to B- from C on 5/11/2018 due to a significant increase in the growth index, valuation index and total return index. Earnings per share increased from -$0.2451 to $1.19, EBIT increased 16.55% from $37M to $43.13M, and total revenue increased 6.91% from $273.11M to $292M.
USANA Health Sciences, Inc. (USNA) was upgraded to B- from C on 5/11/2018 due to a significant increase in the growth index, valuation index and total return index. Earnings per share increased from -$0.2451 to $1.19, EBIT increased 16.55% from $37M to $43.13M, and total revenue increased 6.91% from $273.11M to $292M.
C
Hold
5/2/2018Downgrade
USANA Health Sciences, Inc. (USNA) was downgraded to C from C+ on 5/2/2018 due to a noticeable decline in the valuation index and volatility index.
USANA Health Sciences, Inc. (USNA) was downgraded to C from C+ on 5/2/2018 due to a noticeable decline in the valuation index and volatility index.
C
Hold
3/5/2018Downgrade
USANA Health Sciences, Inc. (USNA) was downgraded to C+ from B on 3/5/2018 due to a significant decline in the growth index, valuation index and efficiency index. Earnings per share declined from $0.97 to -$0.2451, and net income declined 124.62% from $23.77M to -$5.85M.
USANA Health Sciences, Inc. (USNA) was downgraded to C+ from B on 3/5/2018 due to a significant decline in the growth index, valuation index and efficiency index. Earnings per share declined from $0.97 to -$0.2451, and net income declined 124.62% from $23.77M to -$5.85M.
B
Buy
3/1/2018Upgraded
USANA Health Sciences, Inc. (USNA) was upgraded to B from B- on 3/1/2018 due to an increase in the total return index.
USANA Health Sciences, Inc. (USNA) was upgraded to B from B- on 3/1/2018 due to an increase in the total return index.
B
Buy
2/12/2018Downgrade
USANA Health Sciences, Inc. (USNA) was downgraded to B- from B on 2/12/2018 due to a decline in the volatility index.
USANA Health Sciences, Inc. (USNA) was downgraded to B- from B on 2/12/2018 due to a decline in the volatility index.
B
Buy
1/16/2018Upgraded
USANA Health Sciences, Inc. (USNA) was upgraded to B from B- on 1/16/2018 due to a large increase in the total return index and volatility index.
USANA Health Sciences, Inc. (USNA) was upgraded to B from B- on 1/16/2018 due to a large increase in the total return index and volatility index.
B
Buy
11/28/2017Upgraded
USANA Health Sciences, Inc. (USNA) was upgraded to B- from C+ on 11/28/2017 due to an increase in the volatility index.
USANA Health Sciences, Inc. (USNA) was upgraded to B- from C+ on 11/28/2017 due to an increase in the volatility index.
C
Hold
8/1/2017Downgrade
USANA Health Sciences, Inc. (USNA) was downgraded to C+ from B- on 8/1/2017 due to a decline in the total return index.
USANA Health Sciences, Inc. (USNA) was downgraded to C+ from B- on 8/1/2017 due to a decline in the total return index.
B
Buy
7/17/2017Upgraded
USANA Health Sciences, Inc. (USNA) was upgraded to B- from C+ on 7/17/2017 due to an increase in the total return index, volatility index and valuation index.
USANA Health Sciences, Inc. (USNA) was upgraded to B- from C+ on 7/17/2017 due to an increase in the total return index, volatility index and valuation index.
C
Hold
6/30/2017Downgrade
USANA Health Sciences, Inc. (USNA) was downgraded to C+ from B- on 6/30/2017 due to a decline in the total return index.
USANA Health Sciences, Inc. (USNA) was downgraded to C+ from B- on 6/30/2017 due to a decline in the total return index.
B
Buy
6/15/2017Upgraded
USANA Health Sciences, Inc. (USNA) was upgraded to B- from C+ on 6/15/2017 due to an increase in the total return index, growth index and solvency index. The quick ratio increased from 1.39 to 1.59, EBIT increased 3.3% from $31.84M to $32.89M, and total revenue increased 0.96% from $252.9M to $255.32M.
USANA Health Sciences, Inc. (USNA) was upgraded to B- from C+ on 6/15/2017 due to an increase in the total return index, growth index and solvency index. The quick ratio increased from 1.39 to 1.59, EBIT increased 3.3% from $31.84M to $32.89M, and total revenue increased 0.96% from $252.9M to $255.32M.
C
Hold
5/1/2017Downgrade
USANA Health Sciences, Inc. (USNA) was downgraded to C+ from B- on 5/1/2017 due to a noticeable decline in the volatility index and growth index. Earnings per share declined from $1.2 to $0.87, EBIT declined 11.15% from $35.83M to $31.84M, and total revenue declined 0.52% from $254.22M to $252.9M.
USANA Health Sciences, Inc. (USNA) was downgraded to C+ from B- on 5/1/2017 due to a noticeable decline in the volatility index and growth index. Earnings per share declined from $1.2 to $0.87, EBIT declined 11.15% from $35.83M to $31.84M, and total revenue declined 0.52% from $254.22M to $252.9M.
B
Buy
1/30/2017Downgrade
USANA Health Sciences, Inc. (USNA) was downgraded to B- from B on 1/30/2017 due to a decline in the total return index.
USANA Health Sciences, Inc. (USNA) was downgraded to B- from B on 1/30/2017 due to a decline in the total return index.
B
Buy
1/9/2017Upgraded
USANA Health Sciences, Inc. (USNA) was upgraded to B from B- on 1/9/2017 due to an increase in the volatility index, valuation index and total return index.
USANA Health Sciences, Inc. (USNA) was upgraded to B from B- on 1/9/2017 due to an increase in the volatility index, valuation index and total return index.
B
Buy
8/11/2016Upgraded
USANA Health Sciences Inc. (USNA) was upgraded to B- from C+ on 8/11/2016 due to a substantial increase in the growth index, solvency index and volatility index. Operating cash flow increased 156.15% from $13.47M to $34.51M, debt to equity declined from 0.27 to 0, and earnings per share increased from $1.77 to $2.07.
USANA Health Sciences Inc. (USNA) was upgraded to B- from C+ on 8/11/2016 due to a substantial increase in the growth index, solvency index and volatility index. Operating cash flow increased 156.15% from $13.47M to $34.51M, debt to equity declined from 0.27 to 0, and earnings per share increased from $1.77 to $2.07.
C
Hold
5/13/2016Downgrade
USANA Health Sciences Inc. (USNA) was downgraded to C+ from B- on 5/13/2016 due to a significant decline in the growth index, volatility index and valuation index. Operating cash flow declined 63.54% from $36.95M to $13.47M, EBIT declined 4.65% from $35.14M to $33.5M, and earnings per share declined from $1.8302 to $1.77.
USANA Health Sciences Inc. (USNA) was downgraded to C+ from B- on 5/13/2016 due to a significant decline in the growth index, volatility index and valuation index. Operating cash flow declined 63.54% from $36.95M to $13.47M, EBIT declined 4.65% from $35.14M to $33.5M, and earnings per share declined from $1.8302 to $1.77.
B
Buy
3/11/2016Downgrade
USANA Health Sciences Inc. (USNA) was downgraded to B- from B+ on 3/11/2016 due to a significant decline in the volatility index, total return index and solvency index. The quick ratio declined from 1.52 to 1.18.
USANA Health Sciences Inc. (USNA) was downgraded to B- from B+ on 3/11/2016 due to a significant decline in the volatility index, total return index and solvency index. The quick ratio declined from 1.52 to 1.18.
B
Buy
2/26/2016Downgrade
USANA Health Sciences Inc. (USNA) was downgraded to B+ from A- on 2/26/2016 due to a major decline in the volatility index and total return index.
USANA Health Sciences Inc. (USNA) was downgraded to B+ from A- on 2/26/2016 due to a major decline in the volatility index and total return index.
A
Buy
11/18/2015Downgrade
USANA Health Sciences Inc. (USNA) was downgraded to A- from A on 11/18/2015 due to a significant decline in the total return index.
USANA Health Sciences Inc. (USNA) was downgraded to A- from A on 11/18/2015 due to a significant decline in the total return index.
A
Buy
8/11/2015Upgraded
USANA Health Sciences Inc. (USNA) was upgraded to A from A- on 8/11/2015 due to an increase in the total return index.
USANA Health Sciences Inc. (USNA) was upgraded to A from A- on 8/11/2015 due to an increase in the total return index.
A
Buy
7/27/2015Downgrade
USANA Health Sciences Inc. (USNA) was downgraded to A- from A on 7/27/2015 due to a large decline in the volatility index, growth index and solvency index. Operating cash flow declined 37.65% from $37.79M to $23.56M, earnings per share declined from $1.6486 to $1.5, and EBIT declined 8.74% from $32.64M to $29.79M.
USANA Health Sciences Inc. (USNA) was downgraded to A- from A on 7/27/2015 due to a large decline in the volatility index, growth index and solvency index. Operating cash flow declined 37.65% from $37.79M to $23.56M, earnings per share declined from $1.6486 to $1.5, and EBIT declined 8.74% from $32.64M to $29.79M.
A
Buy
5/8/2015Upgraded
USANA Health Sciences Inc. (USNA) was upgraded to A from A- on 5/8/2015 due to an increase in the volatility index and total return index.
USANA Health Sciences Inc. (USNA) was upgraded to A from A- on 5/8/2015 due to an increase in the volatility index and total return index.
A
Buy
4/9/2015Downgrade
USANA Health Sciences Inc. (USNA) was downgraded to A- from A on 4/9/2015 due to a decline in the total return index and valuation index.
USANA Health Sciences Inc. (USNA) was downgraded to A- from A on 4/9/2015 due to a decline in the total return index and valuation index.
A
Buy
3/19/2015Upgraded
USANA Health Sciences Inc. (USNA) was upgraded to A from A- on 3/19/2015 due to an increase in the growth index, valuation index and solvency index. Debt to equity declined from 0.05 to 0, the quick ratio increased from 0.83 to 1.14, and total revenue increased 18.72% from $191.94M to $227.87M.
USANA Health Sciences Inc. (USNA) was upgraded to A from A- on 3/19/2015 due to an increase in the growth index, valuation index and solvency index. Debt to equity declined from 0.05 to 0, the quick ratio increased from 0.83 to 1.14, and total revenue increased 18.72% from $191.94M to $227.87M.
A
Buy
2/23/2015Downgrade
USANA Health Sciences Inc. (USNA) was downgraded to A- from A on 2/23/2015 due to a large decline in the volatility index and total return index.
USANA Health Sciences Inc. (USNA) was downgraded to A- from A on 2/23/2015 due to a large decline in the volatility index and total return index.
A
Buy
12/10/2014Upgraded
USANA Health Sciences Inc. (USNA) was upgraded to A from A- on 12/10/2014 due to a significant increase in the total return index, volatility index and growth index. Operating cash flow increased 25.59% from $28.78M to $36.15M, earnings per share increased from $1.36 to $1.47, and total revenue increased 1.96% from $188.26M to $191.94M.
USANA Health Sciences Inc. (USNA) was upgraded to A from A- on 12/10/2014 due to a significant increase in the total return index, volatility index and growth index. Operating cash flow increased 25.59% from $28.78M to $36.15M, earnings per share increased from $1.36 to $1.47, and total revenue increased 1.96% from $188.26M to $191.94M.
A
Buy
10/31/2014Upgraded
USANA Health Sciences Inc. (USNA) was upgraded to A- from B+ on 10/31/2014 due to a large increase in the growth index and volatility index. Operating cash flow increased 1,065.69% from $2.47M to $28.78M, earnings per share increased from $1.15 to $1.36, and EBIT increased 15.78% from $25.12M to $29.09M.
USANA Health Sciences Inc. (USNA) was upgraded to A- from B+ on 10/31/2014 due to a large increase in the growth index and volatility index. Operating cash flow increased 1,065.69% from $2.47M to $28.78M, earnings per share increased from $1.15 to $1.36, and EBIT increased 15.78% from $25.12M to $29.09M.
B
Buy
6/12/2014Downgrade
USANA Health Sciences Inc. (USNA) was downgraded to B+ from A- on 6/12/2014 due to a noticeable decline in the volatility index and valuation index.
USANA Health Sciences Inc. (USNA) was downgraded to B+ from A- on 6/12/2014 due to a noticeable decline in the volatility index and valuation index.
A
Buy
5/12/2014Downgrade
USANA Health Sciences Inc. (USNA) was downgraded to A- from A on 5/12/2014 due to a significant decline in the growth index, total return index and volatility index. Operating cash flow declined 92.8% from $34.3M to $2.47M, earnings per share declined from $1.3997 to $1.15, and EBIT declined 13.38% from $29M to $25.12M.
USANA Health Sciences Inc. (USNA) was downgraded to A- from A on 5/12/2014 due to a significant decline in the growth index, total return index and volatility index. Operating cash flow declined 92.8% from $34.3M to $2.47M, earnings per share declined from $1.3997 to $1.15, and EBIT declined 13.38% from $29M to $25.12M.
A
Buy
5/5/2014Upgraded
USANA Health Sciences Inc. (USNA) was upgraded to A from A- on 5/5/2014 due to a noticeable increase in the growth index, volatility index and valuation index. Operating cash flow increased 98.3% from $17.3M to $34.3M, earnings per share increased from $1.16 to $1.3997, and total revenue increased 7.24% from $173.69M to $186.27M.
USANA Health Sciences Inc. (USNA) was upgraded to A from A- on 5/5/2014 due to a noticeable increase in the growth index, volatility index and valuation index. Operating cash flow increased 98.3% from $17.3M to $34.3M, earnings per share increased from $1.16 to $1.3997, and total revenue increased 7.24% from $173.69M to $186.27M.
NYSE
03/10/2025 11:20AM Eastern
Quotes delayed
